Medication adherence is a persistent healthcare problem. A prescribed medicine cannot work as intended if it is not taken, yet clinicians often have limited visibility into what happens after the prescription leaves the office.
Proteus Digital Health approached that uncertainty with unusual technical ambition. Its ingestible sensor, made from materials that could generate a signal after contact with stomach fluid, worked with a wearable patch and software. The system could record an ingestion event and share information selected by the patient.
The regulatory path was substantial. The FDA cleared components of the Proteus system, and in 2017 approved Abilify MyCite, an Otsuka antipsychotic embedded with the Proteus sensor. It was widely described as the first digital medicine system of its kind.
The approval demonstrated that a drug-device combination could be reviewed and marketed. It did not demonstrate that tracking ingestion would improve adherence or clinical outcomes. FDA materials warned that the product should not be used for real-time or emergency monitoring because detection could be delayed or missed. Contemporary reporting also noted that studies had not established improved adherence.
A signal is not yet an intervention
The complete system asked several people to participate. A patient had to accept the medication, patch, application, and data-sharing arrangement. A clinician or care team had to decide what to do with the information. A health system had to fit the process into care delivery. A payer or partner had to see sufficient value to support the cost.
Those requirements were especially sensitive in serious mental illness, where questions of privacy, consent, trust, and possible coercion were not peripheral. The technology could make an event observable. Observation alone could not resolve why a patient did not take a medicine or determine what response would help.
Proteus raised significant capital and pursued partnerships, but a planned financing involving Otsuka did not close in 2019. The company reduced its workforce and entered bankruptcy proceedings in 2020. Its assets were later acquired. The available evidence does not support a single-cause explanation: financing, commercialization, evidence, workflow, product complexity, and partner strategy all intersected.
The story is not that the sensor failed technically. Its deeper lesson is that healthcare products operate inside relationships. A new stream of data creates value only when someone can interpret it, act on it, and do so in a way the patient experiences as legitimate.
Proteus succeeded at making ingestion visible. The commercial challenge was to make that visibility useful enough, simple enough, and trusted enough for an entire care system to adopt.
Sources and further reading
Keep exploring
Flatiron Health: When do clinical records become research evidence?Foundation Medicine: Turning a genome into a decision.Put the question to work with an AI prompt →Browse all cases →For a discussion tailored to your team, explore a workshop with Julien.